Compass Therapeutics, Inc.
CMPX
$3.72
-$0.06-1.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 850.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 850.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | -- | 850.00K |
| SG&A Expenses | 4.65M | 4.91M | 3.54M | 3.63M | 4.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.07M | 17.97M | 16.57M | 12.24M | 15.90M |
| Operating Income | -21.07M | -17.97M | -16.57M | -12.24M | -15.05M |
| Income Before Tax | -19.88M | -16.63M | -15.03M | -10.48M | -13.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.88M | -16.63M | -15.03M | -10.48M | -13.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.88M | -16.63M | -15.03M | -10.48M | -13.08M |
| EBIT | -21.07M | -17.97M | -16.57M | -12.24M | -15.05M |
| EBITDA | -20.97M | -17.83M | -16.43M | -12.10M | -14.89M |
| EPS Basic | -0.14 | -0.12 | -0.11 | -0.08 | -0.10 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.07 | -0.05 | -0.06 |
| EPS Diluted | -0.14 | -0.12 | -0.11 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.07 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 138.28M | 138.24M | 136.63M | 137.59M | 137.59M |
| Average Diluted Shares Outstanding | 138.28M | 138.24M | 136.63M | 137.59M | 137.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |